{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:02:03Z","timestamp":1784847723396,"version":"3.55.0"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Real-world data on risk stratification and clinical management of patients with primary biliary cholangitis (PBC) are limited. Identification of patients with increased risk for disease progression is, however, important, since they may benefit from more stringent treatment goals and second line therapy.<\/jats:p>\n                  <jats:p>In this study, we retrospectively characterized a cohort of 535 PBC patients from a university hospital in northern Germany. We evaluated risk factors of disease progression, such as inadequate response to ursodeoxycholic acid (UDCA), younger age, vibration-controlled transient elastography (VCTE)-based evidence of progressed fibrosis, and co-morbidities (autoimmune hepatitis variant syndrome or obesity). The aim of this study was to get insights into the characteristics and risk factors of PBC patients which might contribute to an improved patient care.<\/jats:p>\n                  <jats:p>PBC was mainly diagnosed in women (92%), aged between 50 and 69 years at the time of evaluation. The majority of PBC patients were overweight and 27% revealed obesity (BMI \u2265 30 kg\/m2). PBC patients with autoimmune hepatitis variant syndrome (17% in our cohort) showed a similar treatment response to ursodeoxycholic acid (according to Paris II) compared to PBC patients without a variant syndrome (55% versus 57%). Patients younger than 50 years revealed a lower treatment response rate compared to older patients (40% versus 62%). Compared to patients without advanced fibrosis, PBC patients with advanced fibrosis (VCTE values \u2265 10 kPa) had a lower treatment response (65% versus 37%).<\/jats:p>\n                  <jats:p>Identification of risk factors and hepatic co-morbidities is important to optimize the management and treatment of PBC patients.<\/jats:p>","DOI":"10.1055\/a-2857-7915","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:39:39Z","timestamp":1784846379000},"source":"Crossref","is-referenced-by-count":0,"title":["Characterization of a Northern German Primary Biliary Cholangitis Cohort"],"prefix":"10.1055","author":[{"given":"Heike","family":"Bantel","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Germany","place":["Hannover"],"department":["Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Fatih","family":"Kader","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Germany","place":["Hannover"],"department":["Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"John","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Germany","place":["Hannover"],"department":["Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Franck","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Germany","place":["Hannover"],"department":["Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Germany","place":["Hannover"],"department":["Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1055\/s-0039-1697617","article-title":"The pathogenesis of primary biliary cholangitis: A comprehensive review","volume":"40","author":"A Lleo","year":"2020","journal-title":"Semin Liver Dis"},{"key":"ref2","first-page":"349","volume-title":"Primary Biliary Cholangitis","author":"H Bantel","year":"2024"},{"issue":"04","key":"ref3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"D Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1055\/a-2558-5204","article-title":"S3 guideline \u201eRare liver disease \u2013 autoimmune liver diseases from paediatrics to adulthood\u201d of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)","volume":"63","author":"M Sebode","year":"2025","journal-title":"Z Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"KM Boberg","year":"2011","journal-title":"J Hepatol"},{"issue":"05","key":"ref6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/j.1572-0241.2002.05703.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system","volume":"97","author":"JA Talwalkar","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"06","key":"ref7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1440-1746.2004.03372.x","article-title":"Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome","volume":"19","author":"Y Suzuki","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"25906","DOI":"10.1038\/srep25906","article-title":"Evolving trends in female to male incidence and male mortality of primary biliary cholangitis","volume":"6","author":"A Lleo","year":"2016","journal-title":"Sci Rep"},{"issue":"08","key":"ref9","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems","volume":"16","author":"M Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1055\/a-1135-9306","article-title":"Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalence based on ICD codes, yet deficits in medical treatment","volume":"58","author":"M Sebode","year":"2020","journal-title":"Z Gastroenterol"},{"issue":"05","key":"ref11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"K Boonstra","year":"2012","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101132","article-title":"Incidence and prevalence of primary biliary cholangitis in the Netherlands \u2013 A nationwide cohort study","volume":"6","author":"RC de Veer","year":"2024","journal-title":"JHEP Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"WJ Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"KD Lindor","year":"2019","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"C Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"MH Harms","year":"2019","journal-title":"J Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"CF Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"AC Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"C Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"EM Hennes","year":"2008","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"L Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"M Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"C Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"ZM Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/jcm10051061","article-title":"Real-World clinical management of patients with primary biliary cholangitis \u2013 A retrospective multicenter study from Germany","volume":"10","author":"AB Wilde","year":"2021","journal-title":"J Clin Med"},{"issue":"S 1","key":"ref27","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1097\/MEG.0000000000002011","article-title":"Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium","volume":"33","author":"A Pariente","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/ueg2.12095","article-title":"Predictors for incomplete response to ursodeoxycholic acid in primary biliary cholangitis. Data from a national registry of liver disease","volume":"9","author":"H Cortez-Pinto","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1007\/s10620-019-06009-3","article-title":"Symptom burden and treatment response in patients with primary biliary cholangitis (PBC)","volume":"65","author":"L Kaps","year":"2020","journal-title":"Dig Dis Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.3390\/jcm12227047","article-title":"Primary biliary cholangitis (PBC) \u2013 autoimmune hepatitis (AIH) variant syndrome: clinical features, response to therapy and long-term outcome","volume":"12","author":"M Graf","year":"2023","journal-title":"J Clin Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/liv.15720","article-title":"Autoimmune liver diseases and diabetes: A propensity score matched analysis and a proportional meta-analysis","volume":"43","author":"ASH Jensen","year":"2023","journal-title":"Liver Int"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"L Cristoferi","year":"2021","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","article-title":"Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes","volume":"102","author":"MG Silveira","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis","volume":"50","author":"F Yang","year":"2016","journal-title":"Clinic Rev Allerg Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: Treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"CF Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2857-7915.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:39:41Z","timestamp":1784846381000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2857-7915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1055\/a-2857-7915","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}